Greatland launches field activities at Paterson project

Iain Gilbert Sharecast | 13 Oct, 2017 12:24 - Updated: 12:24 | | |

  • 1.90
  • 61.97%0.72
  • Max: 2.03
  • Min: 1.09
  • Volume: 449,047,968
  • MM 200 : n/a
15:45 17/10/17
  • 17,856.73
  • -0.58%-104.14
  • Max: 18,032.08
  • Min: 17,844.61
  • Volume: 0
  • MM 200 : n/a
15:45 17/10/17
  • 1,033.79
  • 0.37%3.84
  • Max: 1,034.12
  • Min: 1,028.05
  • Volume: 0
  • MM 200 : n/a
15:45 17/10/17

Precious and base metals exploration and development firm Greatland Gold announced on Friday that it had begun the first phase of field activities at its Paterson project in Western Australia.

Mobile Metal Ion (MMI) sampling revealed an initial sample spacing of 200 metres by 200 metres across a nine square kilometre radius of Greatland's Havieron target area, with ground gravity surveys set to start before 31 October at both Havieron and Scallywag, which was estimated to host several magnetic anomalies that housed gold and/or copper mineralisation over its 6km by 4km base.

Gervaise Heddle, Greatland's chief executive officer, said, "We are very excited to have started exploration work at the Paterson project on time. The initial MMI sampling campaign at more than twenty Iron-Oxide-Copper-Gold targets will attempt to demonstrate that a relatively low-cost geochemical technique can be used in this region to detect potential Iron-Oxide-Copper-Gold systems."

As of 1100 BST, shares had dropped 3.23% to 1.26p.

More news

15:41 AIM newcomer Cora Gold enters drilling agreement with Target

West Africa-focussed gold exploration company Cora Gold announced on Tuesday that its wholly-owned subsidiary Cora Gold Mali has entered into a contract with Target Drilling, to supply aircore, reverse circulation and diamond core drilling, focusing primarily on its flagship Sanankoro Gold Discovery in South Mali.

15:37 CloudCall raises £3.7m through two placings

Cloud-based software business CloudCall announced on Tuesday that it has raised approximately £3.5m before expenses, by way of a placing of 2,457,774 new ordinary shares at 143.5p.

15:32 Stratex offloads stake in Goldstone Resources

Gold exploration and development company Stratex announced the sale of its 13.7% stake in Goldstone Resources to institutional investors on Tuesday, at a price of 1.6p per share, for total cash consideration of £0.55m.

15:30 NAHB housing market index hits five-month high in October

Sentiment among US housebuilders unexpectedly improved in October, according to data released on Tuesday.

15:28 Fuel costs goose US import prices higher in September

Dearer fuel imports boosted the cost of overseas goods last month, albeit alongside similar-sized gains in export prices.

15:28 Flowtech Fluidpower pumps out solid third quarter

Specialist technical fluid power products supplier Flowtech Fluidpower updated the market on its trading following its third quarter to 30 September on Tuesday, reporting that group revenue during the first nine months of the year was up 34.4%.

15:18 FTSE 100 movers: Pearson surges on results but Merlin gets clobbered

London's FTSE 100 was up 0.3% to 7,546.11 in afternoon trade on Tuesday as investors digested the latest UK inflation figures.

15:17 RhythmOne expecting bumper first half amid acquisition spree

RhythmOne updated the market on its expected performance for the half year to 30 September on Tuesday, reporting revenues of between $112m and $114m, up from $67m in the first half of the 2017 financial year, which the company said was driven by “programmatic platform growth”.

15:16 US industrial production misses forecasts in September

Industrial production in the US rose as expected last month but amid downwards revisions to readings for previous months, especially in manufacturing.

15:07 Chi-Med trials with AstraZeneca show preliminary anti-tumour activity

Hutchison China MediTech - commonly known as Chi-Med - announced on Tuesday that both it and AstraZeneca presented preliminary safety and clinical activity data of savolitinib when given in combination with either Tagrisso (osimertinib) or Iressa (gefitinib) in two Phase Ib/II proof-of-concept trials conducted in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with MET-amplification, who had progressed following first-line treatment with an EGFR inhibitor.